Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TRAVERE THERAPEUTICS, INC.

(TVTX)
  Report
Delayed Quote. Delayed Nasdaq - 12/06 04:00:01 pm
27.77 USD   +0.58%
11/11Travere Therapeutics to Present at Upcoming Investor Conferences
GL
11/09INSIDER SELL : Travere Therapeutics
MT
11/03INSIDER SELL : Travere Therapeutics
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Travere Therapeutics : Chief Medical Officer to Shift to Adviser Role at Yearend

10/12/2021 | 05:12pm EST


ę MT Newswires 2021
All news about TRAVERE THERAPEUTICS, INC.
11/11Travere Therapeutics to Present at Upcoming Investor Conferences
GL
11/09INSIDER SELL : Travere Therapeutics
MT
11/03INSIDER SELL : Travere Therapeutics
MT
11/02Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week..
GL
10/29Travere Therapeutics' Q3 Adjusted Loss Widens, Revenue Grows
MT
10/29Wedbush Lifts Price Target on Travere Therapeutics to $20 From $14, Maintains Neutral R..
MT
10/29Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
10/29Quarterly Report (Form 10-Q)
PU
10/28Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational Pr..
PU
10/28Travere Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
More news
Analyst Recommendations on TRAVERE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 225 M - -
Net income 2021 -172 M - -
Net cash 2021 299 M - -
P/E ratio 2021 -9,61x
Yield 2021 -
Capitalization 1 700 M 1 700 M -
EV / Sales 2021 6,23x
EV / Sales 2022 6,98x
Nbr of Employees 262
Free-Float 95,5%
Chart TRAVERE THERAPEUTICS, INC.
Duration : Period :
Travere Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TRAVERE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 27,77 $
Average target price 36,00 $
Spread / Average Target 29,6%
EPS Revisions
Managers and Directors
Eric M. Dube President, Chief Executive Officer & Director
Laura M. Clague Chief Financial Officer
Gary A. Lyons Chairman
William E. Rote Senior VP, Head-Research & Development
Noah L. Rosenberg Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TRAVERE THERAPEUTICS, INC.2.70%1 700
GILEAD SCIENCES, INC.19.29%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.78%63 017
VERTEX PHARMACEUTICALS-13.24%52 137